Latest Commercial Readiness News

Australian Vanadium Limited (AVL) reports strong progress on its integrated vanadium project, moving closer to final feasibility and advancing its utility-scale battery storage system, Project Lumina.

Rhythm Biosciences has successfully validated its ColoSTAT® colorectal cancer test, secured its first strategic partnership for Genetype, and secured $1 million in non-dilutive funding, setting the stage for a transformative FY26.

Carnegie Clean Energy has made significant strides in advancing its wave energy technologies, signing key MOUs and achieving critical milestones in the ACHIEVE Programme during the June 2025 quarter.

First Graphene Limited reports over A$1.2 million in annual income, driven by new commercial orders and breakthrough graphene applications in mining safety boots and cement additives.

Jindalee Lithium progresses its McDermitt Lithium Project with strong US government support and a promising new refining technology partnership, aiming to enhance sustainability and reduce costs.

Actinogen Medical has reached a key milestone in its XanaMIA phase 2b/3 Alzheimer’s trial with over 100 participants enrolled, setting the stage for an interim analysis in January 2026. The company also secured a $13.8 million non-dilutive R&D funding facility to support ongoing development.

Global Uranium and Enrichment Limited’s investee Ubaryon has sealed a binding agreement with uranium giant Urenco, unlocking a A$5 million investment and technical collaboration to accelerate a novel uranium enrichment technology.

Brazilian Critical Minerals Ltd has reported significant progress at its Ema rare earths project, achieving high recovery rates from in-situ recovery (ISR) tests and securing a $4 million capital raise to accelerate development.

Sovereign Metals’ latest testwork confirms Kasiya graphite’s premium quality amid sweeping US tariffs on Chinese imports, spotlighting its potential as a strategic non-Chinese supply source for battery manufacturers.

Brazilian Critical Minerals reports exceptional pilot field trial results at its Ema rare earth project, advancing permitting and feasibility studies while attracting strong market interest.

EVE Health Group has secured regulatory approval enabling prescription access for its lead products Libbo and Dyspro in Australia, setting the stage for a commercial rollout before the end of 2025.

PainChek has completed its final FDA submission for the PainChek Adult App, targeting the US long-term care market with a potential $100 million annual opportunity. A regulatory decision is expected within 75 days, setting the stage for rapid commercialisation.